Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
Background
Cited by
Items 101–200 of 409
Determination of Sesquiterpenes in Wines by HS-SPME Coupled with GC-MS
Cincotta, F., Verzera, A., Tripodi, G., & Condurso, C. (2015) · Chromatography · doi:10.3390/chromatography2030410 · Cited by 42
“These compounds are described as possessing anti-inflammatory properties [12], antibacterial properties including enhancement of bacterial susceptibility to antibiotics [13], vanticarcinogenic [14] and antioxidant effects [15].”
BackgroundHeffernan, A. J., Lim, S. M. S., Lipman, J., & Roberts, J. A. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100970 · Cited by 48
Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children
Béranger, A., Oualha, M., Urien, S., Genuini, M., Renolleau, S., Aboura, R., Hirt, D., Heilbronner, C., Toubiana, J., Tréluyer, J., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0602-9 · Cited by 41
Delivering precision antimicrobial therapy through closed-loop control systems
Rawson, T. M., O’Hare, D., Herrero, P., Sharma, S., Moore, L. S. P., de Barra, E., Roberts, J. A., Gordon, A. C., Hope, W. W., Georgiou, P., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx458 · Cited by 42
Bricheux, A., Lenggenhager, L., Hughes, S., Karmime, A., Lescuyer, P., & Huttner, A. C. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.020 · Cited by 38
Mulla, H., Peek, G. J., Harvey, C., Westrope, C. A., Kidy, Z., & Ramaiah, R. (2013) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1304100112 · Cited by 37
Year in review 2011: Critical Care - infection
Afshari, A., Pagani, L., & Harbarth, S. (2012) · Critical Care · doi:10.1186/cc11421 · Cited by 37
“In another systematic review, Gonçalves-Pereira and Póvoa examined the pharmacokinetics of six diff erent βlactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) in septic ICU patients [30].”
BackgroundBraune, S. A., König, C., Roberts, J. A., Nierhaus, A., Steinmetz, O. M., Baehr, M., Kluge, S., & Langebrake, C. (2018) · Critical Care · doi:10.1186/s13054-018-1940-1 · Cited by 38
Neugebauer, S., Wichmann, C., Bremer-Streck, S., Hagel, S., & Kiehntopf, M. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000570 · Cited by 39
Fawaz, S., Barton, S., & Nabhani‐Gebara, S. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05149-6 · Cited by 36
Al‐Shaer, M. H., Neely, M. N., Liu, J., Cherabuddi, K., Venugopalan, V., Rhodes, N. J., Klinker, K. P., Scheetz, M. H., & Peloquin, C. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00745-20 · Cited by 37
“All the previous studies, as well as ours, highlight the variability in cefepime PK parameters for ICU patients, which will affect target attainment for each patient (9, 10).”
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review
Sanz-Codina, M., & Zeitlinger, M. A. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01102-1 · Cited by 50
“Therefore, their limited tissue distribution and the fluctuations of renal function in the critically ill make these antibiotics very susceptible to pharmacokinetic variability and target attainment failure [35, 36].”
BackgroundPetersson, J., Giske, C. G., & Eliasson, E. (2016) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12808 · Cited by 36
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Roehr, A. C., Frey, O. R., Koeberer, A., Fuchs, T., Roberts, J. A., & Brinkmann, A. (2015) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000377 · Cited by 34
“A large number of clinical pharmacokinetic studies have been developing general anti-infective dosing recommendations based on rather small numbers of patient, accepting that this particular patient population is subject to huge pharmacokinetic variability (4).”
BackgroundBakdach, D., Elajez, R., Bakdach, A. R., Awaisu, A., PASCALE, G. D., & Hssain, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236898 · Cited by 43
“Readers are encouraged to refer to the previous published literature for more in-depth information [17,25,91,92] Although the “one size fits all” approach has been well-described to be inappropriate across such critically ill population, more studies are still required to properly adopt patient-centered treatment appr…”
BackgroundDaptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients
D’Avolio, A., Pensi, D., Baietto, L., Pacini, G., Perri, G. D., & Rosa, F. G. D. (2016) · Drugs · doi:10.1007/s40265-016-0610-3 · Cited by 35
Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients
Cheng, V., Abdul-Aziz, M. H., Roberts, J. A., & Shekar, K. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563596 · Cited by 37
“Volume of distribution (Vd) increases [36] and profound increases or decreases in renal drug clearance”
BackgroundApproach to febrile neutropenia in patients undergoing treatments for hematologic malignancies
Stohs, E. J., Abbas, A., & Freifeld, A. G. (2024) · Transplant Infectious Disease · doi:10.1111/tid.14236 · Cited by 40
Matusik, É., Boidin, C., Friggeri, A., Richard, J., Bitker, L., Roberts, J. A., & Goutelle, S. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000941 · Cited by 35
Al‐Shaer, M. H., Maranchick, N. F., Bai, C., Maguigan, K. L., Shoulders, B. R., Felton, T., Mathew, S. K., Mardini, M., & Peloquin, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-22 · Cited by 35
“MIC were suggested in the literature (20 – 22), clinicians need to keep in mind that the beta-lactam concentration in plasma might differ from the concentration at the site of infection (23 – 25).”
BackgroundTøttrup, M., Bibby, B. M., Hardlei, T. F., Bue, M., Kerrn‐Jespersen, S., Fuursted, K., Søballé, K., & Birke‐Sørensen, H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03857-14 · Cited by 32
The use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 33
“Previous work has shown that the volume of distribution can be twofold greater in the critically ill population for hydrophilic antibiotics such as the aminoglycosides,[116] β-lactams [117,118] and glycopeptides.”
BackgroundSieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07653-3 · Cited by 35
Lertwattanachai, T., Montakantikul, P., Tangsujaritvijit, V., Sanguanwit, P., Sueajai, J., Auparakkitanon, S., & Dilokpattanamongkol, P. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00442-7 · Cited by 35
Cies, J. J., Moore, W. S., Conley, S. B., Dickerman, M. J., Small, C., Carella, D. M., SHEA, P. A., Parker, J., & Chopra, A. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.1.92 · Cited by 33
Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis
Korbila, I. P., Tansarli, G. S., Karageorgopoulos, D. E., Vardakas, K. Z., & Falagas, M. E. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.44 · Cited by 30
Song, X., Wu, Y. P., Cao, L., Yao, D., & Long, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02777 · Cited by 31
Verhaeghe, J., Dhaese, S. A. M., Corte, T. D., Mijnsbrugge, D. V., Aardema, H., Zijlstra, J. G., Verstraete, A., Stove, V. V., Colin, P. J., Ongenae, F., et al. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-01970-y · Cited by 34
Gonçalves-Pereira, J., Fernandes, J., Duarte, A. R., & Fernandes, S. M. (2022) · Antibiotics · doi:10.3390/antibiotics11121839 · Cited by 40
Self-citationTsai, D., Stewart, P., Goud, R., Gourley, S., Hewagama, S. S., Krishnaswamy, S., Wallis, S. C., Lipman, J., & Roberts, J. A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.021 · Cited by 29
Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review
Boidin, C., Moshiri, P., Dahyot‐Fizelier, C., Goutelle, S., & Lefeuvre, S. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.07.016 · Cited by 33
Moniz, P., Coelho, L., & Póvoa, P. M. S. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01558-w · Cited by 38
“In the case of hydrophilic AMT (beta-lactams, aminoglycosides, daptomycin, glycopeptides), this can potentiate Vd expansion [67].”
BackgroundSelf-citationMaimongkol, P., Yonwises, W., Anugulruengkitt, S., Sophonphan, J., Treyaprasert, W., & Wacharachaisurapol, N. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.052 · Cited by 27
Casals, G., Hernández, C., Hidalgo, S., Morales‐Romero, B., López‐Púa, Y., Castro, P., Fortuna, V., Martínez, J. A., & Brunet, M. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.08.002 · Cited by 27
Brinkmann, A., Röhr, A. C., Koeberer, A., Fuchs, T., Preisenberger, J., Krüger, W. A., & Frey, O. R. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0213-5 · Cited by 28
Klastrup, V., Thorsted, A., Storgaard, M., Christensen, S., Friberg, L. E., & Öbrink‐Hansen, K. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02556-19 · Cited by 30
“creased variability in (unbound) antibiotic plasma concentration, which makes achievement of optimal antibiotic exposure in this patient population a challenge (6).”
BackgroundSchießer, S., Hitzenbichler, F., Kees, M. G., Kratzer, A., Lubnow, M., Salzberger, B., Kees, F., & Dorn, C. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000827 · Cited by 27
“Genius, n (%) 3 (43) 6 (29)* 2 (14) 1 (17)”
König, C., Both, A., Rohde, H., Kluge, S., Frey, O. R., Röhr, A. C., & Wichmann, D. (2021) · Antibiotics · doi:10.3390/antibiotics10060649 · Cited by 28
“However, altered pharmacokinetics of beta-lactam antibiotics especially in the critically ill patient cohort is a well-known problem when it comes to optimal drug dosing [7].”
BackgroundInfusional β-lactam antibiotics in febrile neutropenia
Abbott, I. J., & Roberts, J. A. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835915c2 · Cited by 26
Lautrette, A., Phan, T.-N., Ouchchane, L., Hssain, A. A., Tixier, V., Heng, A.-É., & Souweine, B. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-124 · Cited by 29
Dose modulation: A new concept of antibiotic therapy in the critically ill patient?
Gonçalves-Pereira, J., & Paiva, J.-A. (2013) · Journal of Critical Care · doi:10.1016/j.jcrc.2012.11.018 · Cited by 27
Self-citationYang, N., Wang, J., Xie, Y., Ding, J., Wu, C., Liu, J., & Pei, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838205 · Cited by 32
“The physiological and pathological conditions in critically ill patients cause significant β-lactam pharmacokinetic (PK) and pharmacodynamics (PD) variability (Gonçalves-Pereira and Póvoa, 2011; Roberts et al., 2014a).”
BackgroundZhang, Z., Patel, Y. T., Fiedler‐Kelly, J., Feng, H.-P., Bruno, C. J., & Gao, W. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1733 · Cited by 26
A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
Cattrall, J. W. S., Asín‐Prieto, E., Freeman, J., Trocóniz, I. F., & Kirby, A. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03679-9 · Cited by 25
“But given the conducted studies used PK data from healthy volunteers and intensive care unit patients, both groups known to have higher levels of renal excretion than other groups, it is possible that studies in relevant populations may be more favourable to assessments of antibiotic efficacies [38].”
Gonçalves-Pereira, J., Oliveira, B., Janeiro, S., Berger‐Estilita, J., Monteiro, C., Salgueiro, A., Vieira, A. U. C., Gouveia, J., Paulino, M. C., Bento, L. F. N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049845 · Cited by 24
Self-citationCommunity-acquired pneumonia: identification and evaluation of nonresponders
Gonçalves-Pereira, J., Conceição, C., & Póvoa, P. M. S. R. (2013) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936112469017 · Cited by 25
“In fact, in severely infected patients, an increase in the volume of distribution [Gonçalves-Pereira and Póvoa, 2011] of some antibiotics (especially blactams) is always to be expected, in particular in the presence of organ failure [Ulldemolins et al. 2011], due both to host response to sepsis…”
BackgroundSelf-citationOptimizing antimicrobial therapy in critically ill patients
Pagani, L., Vitrat, V., Hautefeuille, S., Janssen, C., Bougon, D., & Sirodot, M. (2014) · Infection and Drug Resistance · doi:10.2147/idr.s44357 · Cited by 29
“As mentioned above, PK properties of β-lactams in ICU patients may be profoundly altered due to the dynamic and unpredictable pathophysiological changes that occur in severe sepsis.(85) Therapeutic drug monitoring (TDM) may be useful to improve β-lactam dosing, as any assumptions about drug concentrations are unreliab…”
BackgroundSimon, P., Petroff, D., Busse, D., Heyne, J., Girrbach, F. F., Dietrich, A., Kratzer, A., Zeitlinger, M. A., Kloft, C., Kees, F., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9120931 · Cited by 23
“The pharmacokinetics of meropenem in humans has been investigated extensively also for critically ill patients [14].”
BackgroundO’Jeanson, A., Larcher, R., Souder, C. L., Djebli, N., & Khier, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00709-w · Cited by 22
Ma, Y., Ran, F., Xin, M., Gou, X., Wang, X., & Wu, X. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.05.007 · Cited by 23
Tazobactam and piperacillin-induced thrombocytopenia: A case report
Chen, H., Fan, Z., Guo, F., Yang, Y., Li, J., Zhang, J., Wang, Y., Le, J., Wang, Z., & Zhu, J. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3062 · Cited by 22
“Tazobactam and piperacillin (TZP) are antibiotics that are used to treat the majority of infections caused by β -lactamase-producing bacteria (4,5).”
Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2017) · Critical Care · doi:10.1186/s13054-017-1871-2 · Cited by 23
“The volume of distribution and drug clearance are the pharmacokinetic parameters of greatest relevance to determining drug dosing requirements, and both parameters may be significantly deranged during critical illness [2, 3].”
BackgroundSelig, D. J., Akers, K. S., Chung, K. K., Pruskowski, K. A., Livezey, J., & Por, E. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15138 · Cited by 21
Helfer, V. E., Zavascki, A. P., Zeitlinger, M. A., de Araújo, B. V., & Costa, T. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00741-22 · Cited by 23
Guilhaumou, R., Chevrier, C., Setti, J.-L., Jouve, É., Marsot, A., Julian, N., Blin, O., Simeone, P., Lagier, D., Mokart, D., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12081289 · Cited by 25
Lheureux, O., Trépo, E., Hites, M., COTTON, F. J., Wolff, F., Surin, R., Créteur, J., Vincent, J., Gustot, T., Jacobs, F., et al. (2015) · Liver International · doi:10.1111/liv.13039 · Cited by 23
“Alcohol, n (%) 29 (76) – Chronic HCV, n (%) 4 (10) – Chronic HBV, n (%) 2 (5) – Nonalcoholic fatty liver disease, n (%) 3 (8) –”
BackgroundŠestáková, N., Theurillat, R., Sendi, P., & Thormann, W. (2017) · Journal of Separation Science · doi:10.1002/jssc.201601446 · Cited by 21
Abdul-Aziz, M. H., McDonald, C., McWhinney, B. C., Ungerer, J. P. J., Lipman, J., & Roberts, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014540610 · Cited by 20
“Significant discordance in β-lactam PK is usually observed in this patient population, and the scenario may lead to subtherapeutic antibiotic exposure.(8,9) Furthermore, flucloxacillin concentrations may be lower in the CSF considering its poor and limited penetration into the CNS.”
BackgroundOptimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles
Hoo, G. S. R., Liew, Y. X., & Kwa, A. L. (2017) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_17_278 · Cited by 25
“7 L/kg) suggests that the drug is concentrated in the plasma (hydrophilic).[6] Fluid resuscitation or the physiologic derangements occurring with increased severity of illness have been shown to increase the Vd of antimicrobials and become significant in septic or critically ill patients because hydrophilic antibiotic…”
BackgroundBouajram, R. H., & Awdishu, L. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.004 · Cited by 20
Barreto, E. F., Chang, J. H. T., Rule, A. D., Mara, K. C., Meade, L. A., Paul, J., Jannetto, P. J., Athreya, A. P., Scheetz, M. H., & for the BLOOM Study Group (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00810-23 · Cited by 24
“Compromise of the endothelial glycocalyx with third spacing of intravenous fluid, large volume resuscitation, cirrhosis, heart failure, and anasarca can each expand the cefepime volume of distribution (4).”
BackgroundUnraveling the impact of therapeutic drug monitoring via machine learning for patients with sepsis
Ates, H. C., Alshanawani, A., Hagel, S., Cotta, M. O., Roberts, J. A., Dincer, C., & Ateş, C. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101681 · Cited by 28
Rigo-Bonnin, R. F., Roig, R. J., Badosa, E. L., Sabater‐Riera, J., Pérez-Fernández, X. L., Cárdenas-Campos, P., Sospedra-Martínez, E., Colom, H., & Alia, P. J. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7910-9 · Cited by 19
“Meropenem concentration values in human plasma, filtratedialysate, and urine are being used for developing a population PK/PD model of MEM in critically ill septic patients receiving CRRT [7, 20].”
MethodJonckheere, S., Neve, N. D., Beenhouwer, H. D., Berth, M., Vermeulen, A., Bocxlaer, J. V., & Colin, P. J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw171 · Cited by 19
Peng, Y., Cheng, Z., & Xie, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00822-22 · Cited by 18
Laporte-Amargós, J., Ulldemolins, M., Puig‐Asensio, M., Tebé, C., Castro, S., Carratalà, J., & Gudiol, C. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.06.023 · Cited by 18
Kanji, S., Roger, C., Taccone, F. S., & Müller, L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2858 · Cited by 21
“35,36 Hypoalbuminemia is common in this population and mainly affects high protein-bound drugs (e.g., echinocandins, cefazolin, ceftriaxone, flucloxacillin, teicoplanin, or antifungal agents such as isavuconazole).”
BackgroundXu, C., Zeng, F., Huang, Y., Xu, Q., Yang, Y. Z., Gong, W., Shi, C., & Zhang, Y. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107021 · Cited by 20
Langan, K. M., Jacob, J., Li, J., Nation, R. L., Bellomo, R., Howden, B. P., & Johnson, P. D. R. (2014) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01471-0 · Cited by 18
Dhaese, S. A. M., Colin, P. J., Willems, H., Heffernan, A. J., Gadeyne, B., Vooren, S. V., Depuydt, P. O., Hoste, E. A. J., Stove, V. V., Verstraete, A., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.024 · Cited by 19
Aboulatta, L., Sugita, H., Wakabayashi, H., Noma, H., & Sasaki, T. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.022 · Cited by 20
Parizkova, R. C., Martínková, J., Havel, E., Šafránek, P., Kaška, M., Astapenko, D., Bezouška, J., Chládek, J., & Černý, V. (2021) · Critical Care · doi:10.1186/s13054-021-03680-9 · Cited by 19
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
Ausman, S. E., Moreland-Head, L., Saleh, O. A., Jannetto, P. J., Rivera, C. G., Stevens, R. W., Wessel, R. J., Wieruszewski, P. M., Barreto, E. F., & For the BLOOM Study group (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1819 · Cited by 19
“tible to the pharmacokinetic derangements observed in the critically ill.(5,6) It is for this reason that BL have been identified as a viable drug class candidate for TDM.”
Barreto, E. F., Chang, J. H. T., Rule, A. D., Mara, K. C., Meade, L. A., Paul, J., Jannetto, P. J., Athreya, A. P., Scheetz, M. H., & For the BLOOM Study Group (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000001011 · Cited by 21
Al‐Shaer, M. H., Philpott, C. D., Droege, C. A., Courter, J. D., Healy, D. P., Droege, M. E., Ernst, N. E., Mueller, E. W., & Peloquin, C. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00144-21 · Cited by 18
“In case of pneumonia, a common infection in the ICU, beta-lactams and cefepime may have variable and poor penetration to the lung tissue and secretions in critically ill patients (6, 27), which may indicate that higher drug plasma concentrations are desirable to achieve the optimal exposure at the site of infection.”
BackgroundDjukic, M., Munz, M., Sörgel, F., Holzgrabe, U., Eiffert, H., & Nau, R. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00437-11 · Cited by 17
“A meta-analysis of 57 studies of 6 different -lactam antibiotics showed a more than 2-fold variation both in the volume of distribution (V) and in total body clearance (CL) (34).”
BackgroundLima, B., Bodeau, S., Quinton, M.-C., Leven, C., Lemaire‐Hurtel, A., & Bennis, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00515-19 · Cited by 17
“This finding is consistent with the high interindividual variability of the cephalosporin pharmacokinetics, especially in critically ill patients (5).”
ResultTheurillat, R., Joneli, J., Wanzenried, U., Schiess, J., Hurni, M., Weber, T., Sendi, P., & Thormann, W. (2016) · Journal of Separation Science · doi:10.1002/jssc.201600271 · Cited by 16
Gatti, M., & Pea, F. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274984 · Cited by 18
“Vd increase of hydrophilic antimicrobials in critical septic patients was shown to be 1.5–2-fold than observed in healthy subjects [44].”
BackgroundInfluentialHypothermia: Pathophysiology and the propensity for infection
Werner, L. M., Kevorkian, R. T., Getnet, D., Rios, K. E., Hull, D. M., Robben, P. M., Cybulski, R. J., & Bobrov, A. G. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.11.029 · Cited by 16
Martín‐Loeches, I., Léone, M., Madách, K., Martin, C., & Einav, S. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000595 · Cited by 16
Pharmacokinetics of Intravitreal Vancomycin and Ceftazidime in Silicone Oil-Filled Macaque Eyes
Imamura, T., Kakinoki, M., Hira, D., Kitagawa, T., Ueshima, S., Kakumoto, M., Terada, T., Kawamoto, I., Murase, M., & Ohji, M. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.3.1 · Cited by 16
Luxton, T., King, N. V., Wälti, C., Jeuken, L. J. C., & Sandoe, J. A. T. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac101 · Cited by 16
de Cacqueray, N., Hirt, D., Zheng, Y., Bille, E., Léger, P. L., Rambaud, J., Toubiana, J., Chosidow, A., Vimont, S., Callot, D., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.05.007 · Cited by 18
Al-Shaer, M. H., Maguigan, K., Ashton, J., Venugopalan, V., Droege, M. E., Philpott, C. D., Droege, C. A., Healy, D. P., Mueller, E. W., & Peloquin, C. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-21 · Cited by 15
“CRRT modality, n (%) CVVH CVVHD SLED 8 (80) 2 (20) 0 4 (100) 0 0 109 (98) 0 7 (6)”
C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
Zhao, Y., Xiao, C., Hou, J., Wu, J., Xiao, Y., Zhang, B., Sandaradura, I., Luo, H., Li, J., & Yan, M. (2022) · Antibiotics · doi:10.3390/antibiotics11050670 · Cited by 15
“The pathophysiological process of critically ill patients is more complex [45,46], and they exhibit greater inter-individual variability [47].”
BackgroundMa, Y., Zhang, M., Yang, J., Zhu, L., Dai, J., & Wu, X. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106342 · Cited by 16
Riezk, A., Wilson, R. C., Rawson, T. M., Vasikasin, V., Arkel, P., Ferris, T. J., Haigh, L. D., Cass, A. E. G., & Holmes, A. H. (2023) · Analytical Methods · doi:10.1039/d2ay01276f · Cited by 17
Antimicrobial Pharmacokinetics and Pharmacodynamics
Jarrell, A. S., Kruer, R. M., Johnson, D., & Lipsett, P. A. (2015) · Surgical Infections · doi:10.1089/sur.2014.180 · Cited by 17
“The ratio between the amounts of drug in the body and the serum concentration is referred to as the volume of distribution (V D ) [9].”
InfluentialAbdul-Aziz, M. H., Driver, E., Lipman, J., & Roberts, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1484452 · Cited by 15
“Some of the more important PK parameters for antibiotics are (1) volume of distribution (Vd); (2) clearance (CL); (3) maximum drug concentration over a dosing interval (Cmax); (4) minimum drug concentration over a dosing interval (Cmin); and (5) area under the concentration–time curve from 0 to 24 h at steady state (A…”
BackgroundResultInfluentialThémans, P., Marquet, P., Winkin, J. J., & Musuamba, F. T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0268-x · Cited by 15
Buning, A. W., Hodiamont, C. J., Lechner, N. M., Schokkin, M., Elbers, P., Juffermans, N. P., Mathôt, R. A. A., de Jong, M. D., & van Hest, R. M. (2021) · Antibiotics · doi:10.3390/antibiotics10060612 · Cited by 14
“For ceftazidime, the PK/PD target in critically ill patients is reached when the free (f) drug plasma concentration is maintained above the minimum inhibitory concentration (MIC) for 100% of a dosing interval [8].”
BackgroundKassel, L. E., Matre, E. T. V., Foster, C. J., Fish, D. N., Mueller, S. W., Sherman, D. S., Wempe, M. F., MacLaren, R., Neumann, R. T., & Kiser, T. H. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2156 · Cited by 15
Luxton, T., King, N. V., Wälti, C., Jeuken, L. J. C., & Sandoe, J. A. T. (2022) · Antibiotics · doi:10.3390/antibiotics11101311 · Cited by 14
Antibiotic dosing for multidrug-resistant pathogen pneumonia
Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000348 · Cited by 17
Hatti, M., Solomonidi, N., Odenholt, I., Tham, J., & Resman, F. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3194-x · Cited by 15
“Previous studies performed on patients with severe sepsis, mainly in ICU settings, have also demonstrated great variations in beta-lactam concentration levels [2, 25].”
ResultRam, K., Sheikh, S., Bhati, R. K., Tripathi, C. D., Suri, J. C., & Meshram, G. G. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13482 · Cited by 14
Busse, D., Simon, P., Schmitt, L., Petroff, D., Dorn, C., Dietrich, A., Zeitlinger, M. A., Huisinga, W., Michelet, R., Wrigge, H., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01070-6 · Cited by 14
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.